📊 ANRO Key Takeaways
Is Alto Neuroscience, Inc. (ANRO) a Good Investment?
Alto Neuroscience is a well-capitalized pre-revenue biotech with exceptional financial runway (263.8M cash, 0.06x leverage) and improving loss trajectory, but fundamentals lack the revenue generation and profitability path needed for buy conviction. Success depends entirely on pipeline execution and clinical milestone achievement.
Alto Neuroscience remains a pre-revenue biotech with substantial operating and net losses, negative operating cash flow, and no evidence yet of self-sustaining growth quality. Its balance sheet is a clear support, with $176.48M in cash, very low leverage, and strong liquidity, but the core fundamentals still depend on successful clinical execution rather than operating performance. Until revenue visibility or meaningful loss improvement emerges, the fundamentals skew weak despite solid near-term financial flexibility.
Alto Neuroscience, Inc. Key Strengths (ANRO)
- Exceptional cash position ($263.8M) with 9+ year runway at current burn rate
- Fortress balance sheet with minimal debt ($13.9M) and 0.06x D/E ratio
- Improving loss trajectory with net income losses declining 2.9% YoY and diluted EPS improving 12.4% YoY
- Very strong liquidity, with a 15.69x current and quick ratio supported by $176.48M in cash
- Low balance-sheet leverage, with debt/equity of just 0.11x and equity of $151.14M
- Minimal capital expenditure needs, which helps preserve cash relative to many asset-heavy businesses
ANRO Stock Risks: Alto Neuroscience, Inc. Investment Risks
- Pre-revenue status with no commercialized products generating material revenue
- Significant cash burn rate of $27.1M operating cash outflow annually
- Negative returns on equity (-10.8%) and assets (-9.5%) with no visible path to profitability
- No revenue base, leaving the business entirely reliant on external capital and pipeline progress
- Large ongoing losses, including $-66.36M operating income and $-51.77M operating cash flow
- Weak profitability metrics, with ROE of -41.8% and ROA of -34.2%, indicating poor current capital efficiency
Key Metrics to Watch
- Operating cash burn rate trends and remaining runway
- Clinical development milestone progression and pipeline advancement
- Quarterly revenue initiation and commercial product launch timeline
- Quarterly operating cash burn relative to cash and equivalents
- Any transition from pre-revenue status to recurring collaboration, licensing, or product revenue
Alto Neuroscience, Inc. (ANRO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 20.52x current ratio provides a solid financial cushion.
ANRO Profit Margin, ROE & Profitability Analysis
ANRO vs Healthcare Sector: How Alto Neuroscience, Inc. Compares
How Alto Neuroscience, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Alto Neuroscience, Inc. Stock Overvalued? ANRO Valuation Analysis 2026
Based on fundamental analysis, Alto Neuroscience, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Alto Neuroscience, Inc. Balance Sheet: ANRO Debt, Cash & Liquidity
ANRO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Alto Neuroscience, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.50 indicates the company is currently unprofitable.
ANRO Revenue Growth, EPS Growth & YoY Performance
Alto Neuroscience, Inc. Dividends, Buybacks & Capital Allocation
ANRO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Alto Neuroscience, Inc. (CIK: 0001999480)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANRO
What is the AI rating for ANRO?
Alto Neuroscience, Inc. (ANRO) has a Combined AI Grade of C from Claude (B) and ChatGPT (C) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANRO's key strengths?
Claude: Exceptional cash position ($263.8M) with 9+ year runway at current burn rate. Fortress balance sheet with minimal debt ($13.9M) and 0.06x D/E ratio. ChatGPT: Very strong liquidity, with a 15.69x current and quick ratio supported by $176.48M in cash. Low balance-sheet leverage, with debt/equity of just 0.11x and equity of $151.14M.
What are the risks of investing in ANRO?
Claude: Pre-revenue status with no commercialized products generating material revenue. Significant cash burn rate of $27.1M operating cash outflow annually. ChatGPT: No revenue base, leaving the business entirely reliant on external capital and pipeline progress. Large ongoing losses, including $-66.36M operating income and $-51.77M operating cash flow.
What is ANRO's revenue and growth?
Alto Neuroscience, Inc. reported revenue of N/A.
Does ANRO pay dividends?
Alto Neuroscience, Inc. does not currently pay dividends.
Where can I find ANRO SEC filings?
Official SEC filings for Alto Neuroscience, Inc. (CIK: 0001999480) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANRO's EPS?
Alto Neuroscience, Inc. has a diluted EPS of $-0.80.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ANRO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Alto Neuroscience, Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ANRO stock overvalued or undervalued?
Valuation metrics for ANRO: ROE of -10.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ANRO's AI grade for 2026?
Our dual AI analysis gives Alto Neuroscience, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANRO's free cash flow?
Alto Neuroscience, Inc.'s operating cash flow is $-27.1M, with capital expenditures of $556.0K.
How does ANRO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -10.8% (avg: 15%), current ratio 20.52 (avg: 2).